Jeena Sikho Lifecare Limited , a prominent player in the alternative healthcare sector, has reported robust financial results for the second quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Performance

The company's revenue from operations reached Rs. 190.00 crores in Q2FY26, marking a substantial 66% year-on-year growth from Rs. 114.00 crores in Q2FY25. This performance was complemented by a 9% quarter-over-quarter increase from Rs. 174.00 crores in Q1FY26.

Jeena Sikho's profitability saw a remarkable improvement, with profit after tax (PAT) surging 121% year-on-year to Rs. 59.00 crores. The company also reported a 15% quarter-over-quarter increase in PAT.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 129% year-on-year to Rs. 92.00 crores, maintaining a strong EBITDA margin of 48%.

Operational Highlights

The healthcare provider has expanded its bed capacity, adding 582 beds to reach a total of 2,802 beds. The company reported a 57% occupancy rate across its network of 58 hospitals and 59 clinics.

Jeena Sikho's geographical footprint now spans 23 states and over 100 cities, indicating a wide-reaching presence in the Indian healthcare market.

Strategic Partnerships and Expansion

Jeena Sikho announced a strategic partnership with Chandan Diagnostic. This collaboration provides the company access to 40 lakh privilege cardholders and facilitates the establishment of diagnostic centers across their network.

The partnership aims to enhance patient services by offering free basic blood tests, including ESR, uric acid, CBC, lipid profile, LFT, RFT, and thyroid profile.

Product Development and Technology Integration

The company plans to launch 10 new over-the-counter (OTC) products by the end of the year, expanding its product portfolio. Additionally, Jeena Sikho has partnered with Salesforce to improve data management and customer engagement, indicating a focus on technological integration to enhance operational efficiency.

Management Commentary

Manish Grover, Managing Director of Jeena Sikho Lifecare Limited, commented on the results: "Our continuous hard work and effort has given a great result. We have observed good revenue growth in our product and services segment. This expansional growth shows that we are strongly motivated towards spreading quality alternate health care services to a lot of people."

Grover also highlighted the company's focus on increasing bed occupancy and expanding service footprint, stating, "We are seeing tremendous growth in both our product and services verticals. And it is proof that we are continuously increasing the free cash generation revenue generation."

Future Outlook

While specific guidance for the full fiscal year was not provided, management indicated ongoing efforts to maintain operational efficiency while pursuing expansion. The company's focus on increasing bed occupancy, launching new products, and strategic partnerships suggests a continued growth trajectory in the alternative healthcare sector.

Jeena Sikho Lifecare's strong Q2 FY26 performance underscores its growing presence in the alternative healthcare market, with significant improvements in revenue, profitability, and operational scale.

Jeena Sikho Lifecare Limited (JSLL), a leading Ayurvedic healthcare service provider, has announced robust financial results for the second quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company reported a 66% year-on-year increase in revenue for Q2, reaching ₹189.85 crore, up from ₹114.09 crore in the same quarter last year. This growth was accompanied by a 9% sequential increase from Q1.

JSLL's profitability also saw substantial improvement:

Operational Performance

The company's growth was driven by strong patient volume expansion:

• IPD (In-Patient Department) volumes increased by 57% YoY to 9,614 patients
• OPD (Out-Patient Department) volumes grew by 67% YoY to 1.40 lakh patients
• Day Care volumes surged by 169% YoY to 17,154 patients

Capacity Expansion

Jeena Sikho Lifecare continued its expansion initiatives:

• Three new hospitals became operational during the quarter
• Total operational bed capacity increased to over 2,220 beds
• Approximately 400 additional beds are under development across five facilities

Strategic Focus

The company is increasingly focusing on the private business segment, which offers superior margins compared to the Government Panel segment. This shift in business mix is expected to further strengthen profitability and improve the overall cash-conversion cycle.

Product Development

JSLL's OTC and Medicines division continues to perform strongly, supported by the launch of new products such as Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, and Dr. Sukoon DS. The company plans to launch six additional products in the remainder of the year.

Technology Partnership

Jeena Sikho Lifecare has entered into a strategic partnership with Salesforce to strengthen its technology infrastructure and operational workflows. This collaboration aims to enhance operational efficiency, optimize patient engagement, and broaden access to holistic healthcare across digital platforms.

Management Commentary

Acharya Manish Ji, Managing Director of Jeena Sikho Lifecare, commented on the results: "Our strong performance in Q2 underscores the resilience of our business model and the effectiveness of our strategic initiatives. We remain committed to delivering consistent growth and long-term value for all stakeholders through our ongoing capacity expansion, operational excellence measures, and differentiated product portfolio."